Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

358 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic implications of p16 and HPV discordance in oropharyngeal cancer (HNCIG-EPIC-OPC): a multicentre, multinational, individual patient data analysis.
Mehanna H, Taberna M, von Buchwald C, Tous S, Brooks J, Mena M, Morey F, Grønhøj C, Rasmussen JH, Garset-Zamani M, Bruni L, Batis N, Brakenhoff RH, Leemans CR, Baatenburg de Jong RJ, Klussmann JP, Wuerdemann N, Wagner S, Dalianis T, Marklund L, Mirghani H, Schache A, James JA, Huang SH, O'Sullivan B, Nankivell P, Broglie MA, Hoffmann M, Quabius ES, Alemany L; HNCIG-EPIC group. Mehanna H, et al. Among authors: von buchwald c. Lancet Oncol. 2023 Mar;24(3):239-251. doi: 10.1016/S1470-2045(23)00013-X. Epub 2023 Feb 13. Lancet Oncol. 2023. PMID: 36796393 Free article.
Why in hospital following transoral robotic lingual tonsillectomy?
Larsen MHH, Channir HI, Madsen AKØ, Rubek N, O'Leary P, Kjærgaard T, Kehlet H, von Buchwald C. Larsen MHH, et al. Among authors: von buchwald c. Acta Otolaryngol. 2023 Sep;143(9):796-800. doi: 10.1080/00016489.2023.2265983. Epub 2023 Nov 8. Acta Otolaryngol. 2023. PMID: 37897327 Clinical Trial.
Meta-analysis of ACE inhibitor-induced angioedema identifies novel risk locus.
Mathey CM, Maj C, Eriksson N, Krebs K, Westmeier J, David FS, Koromina M, Scheer AB, Szabo N, Wedi B, Wieczorek D, Amann PM, Löffler H, Koch L, Schöffl C, Dickel H, Ganjuur N, Hornung T, Buhl T, Greve J, Wurpts G, Aygören-Pürsün E, Steffens M, Herms S, Heilmann-Heimbach S, Hoffmann P, Schmidt B, Mavarani L, Andresen T, Sørensen SB, Andersen V, Vogel U, Landén M, Bulik CM; Estonian Biobank Research Team; DBDS Genomic Consortium; Bygum A, Magnusson PKE, von Buchwald C, Hallberg P, Rye Ostrowski S, Sørensen E, Pedersen OB, Ullum H, Erikstrup C, Bundgaard H, Milani L, Rasmussen ER, Wadelius M, Ghouse J, Sachs B, Nöthen MM, Forstner AJ. Mathey CM, et al. Among authors: von buchwald c. J Allergy Clin Immunol. 2024 Apr;153(4):1073-1082. doi: 10.1016/j.jaci.2023.11.921. Epub 2024 Jan 31. J Allergy Clin Immunol. 2024. PMID: 38300190 Free article.
Durable complete response after combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus (TILT-123) in a patient with metastatic mucosal melanoma.
Monberg TJ, Kudling T, Albieri B, Pakola S, Ellebaek E, Donia M, Eefsen RL, von Buchwald C, Kistler C, Santos JM, Clubb J, Haybout L, Westergaard MCW, Quixabeira DCA, Jirovec E, Havunen R, Sorsa S, Cervera-Carrascon V, Hemminki A, Svane IM. Monberg TJ, et al. Among authors: von buchwald c. Immunooncol Technol. 2024 Aug 12;24:100726. doi: 10.1016/j.iotech.2024.100726. eCollection 2024 Dec. Immunooncol Technol. 2024. PMID: 39801682 Free PMC article.
Long-term effect and safety of mesenchymal stromal cell therapy for radiation-induced hyposalivation in head and neck cancer survivors: A randomised, phase-2, trial.
Fenger Carlander AL, Jakobsen KK, Todsen T, Paaske N, Østergaard Madsen AK, Bendtsen SK, Kastrup J, Friborg J, Duch Lynggaard C, Hauge AW, Christensen R, Grønhøj C, von Buchwald C. Fenger Carlander AL, et al. Among authors: von buchwald c. Clin Cancer Res. 2025 Jan 3. doi: 10.1158/1078-0432.CCR-24-2663. Online ahead of print. Clin Cancer Res. 2025. PMID: 39751638
Optical molecular imaging in oral- and oropharyngeal squamous cell carcinoma using a novel uPAR-targeting near-infrared imaging agent FG001 (ICG-Glu-Glu-AE105): An explorative phase II clinical trial.
Andersen AO, Christensen A, Straede K, Lawaetz M, Hahn CH, Rubek N, Wessel I, Lelkaitis G, Kiss K, Paaske N, Poulsen A, von Buchwald C, Kjaer A. Andersen AO, et al. Among authors: von buchwald c. Theranostics. 2025 Jan 1;15(1):52-67. doi: 10.7150/thno.100042. eCollection 2025. Theranostics. 2025. PMID: 39744227 Free PMC article. Clinical Trial.
358 results